SageView Advisory Group’s Editas Medicine EDIT Stock Holding History

SageView Advisory Group’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14	Closed	-$29	–	1110
2025 Q4	$29	Buy	+14	New	+$40	﹤0.01%	2578

Other funds holding EDIT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

SageView Advisory Group's EDIT Position: Q1 2026 in Review

SageView Advisory Group sold out of Editas Medicine (EDIT) in Q1 2026, closing a stake of 14 shares — an estimated $29 sold.

SageView Advisory Group first reported a position in EDIT in Q4 2025 and held it in 1 quarter. The position peaked at $29 in Q4 2025. 208 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

SageView Advisory Group reported no remaining Editas Medicine position as of Q1 2026 after selling out during the quarter.
SageView Advisory Group sold 14 Editas Medicine shares in Q1 2026, an estimated $29.
SageView Advisory Group first reported a position in Editas Medicine in Q4 2025 and held it in 1 quarter.
SageView Advisory Group's Editas Medicine position peaked at $29 in Q4 2025.
208 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.